Unknown

Dataset Information

0

Adeno-associated virus capsid antigen presentation is dependent on endosomal escape.


ABSTRACT: Adeno-associated virus (AAV) vectors are attractive for gene delivery-based therapeutics, but data from recent clinical trials have indicated that AAV capsids induce a cytotoxic T lymphocyte (CTL) response that eliminates transduced cells. In this study, we used traditional pharmacological agents and AAV mutants to elucidate the pathway of capsid cross-presentation in AAV-permissive cells. Endosomal acidification inhibitors blocked AAV2 antigen presentation by over 90%, while proteasome inhibitors completely abrogated antigen presentation. Using mutant viruses that are defective for nuclear entry, we observed a 90% decrease in capsid antigen presentation. Different antigen presentation efficiencies were achieved by selectively mutating virion nuclear localization signals. Low antigen presentation was demonstrated with basic region 1 (BR1) mutants, despite relatively high transduction efficiency, whereas there was no difference in antigen presentation between BR2 and BR3 mutants defective for transduction, as compared with wild-type AAV2. These results suggest that effective AAV2 capsid antigen presentation is dependent on AAV virion escape from the endosome/lysosome for antigen degradation by proteasomes, but is independent of nuclear uncoating. These results should facilitate the design of effective strategies to evade capsid-specific CTL-mediated elimination of AAV-transduced target cells in future clinical trials.

SUBMITTER: Li C 

PROVIDER: S-EPMC3582142 | biostudies-other | 2013 Mar

REPOSITORIES: biostudies-other

altmetric image

Publications

Adeno-associated virus capsid antigen presentation is dependent on endosomal escape.

Li Chengwen C   He Yi Y   Nicolson Sarah S   Hirsch Matt M   Weinberg Marc S MS   Zhang Ping P   Kafri Tal T   Samulski R Jude RJ  

The Journal of clinical investigation 20130201 3


Adeno-associated virus (AAV) vectors are attractive for gene delivery-based therapeutics, but data from recent clinical trials have indicated that AAV capsids induce a cytotoxic T lymphocyte (CTL) response that eliminates transduced cells. In this study, we used traditional pharmacological agents and AAV mutants to elucidate the pathway of capsid cross-presentation in AAV-permissive cells. Endosomal acidification inhibitors blocked AAV2 antigen presentation by over 90%, while proteasome inhibito  ...[more]

Similar Datasets

| S-EPMC5916967 | biostudies-literature
| S-EPMC3655625 | biostudies-literature
| S-EPMC3209291 | biostudies-literature
| S-EPMC2689109 | biostudies-other
| S-EPMC3486322 | biostudies-literature
| S-EPMC1808542 | biostudies-literature
| S-EPMC3457265 | biostudies-literature
| S-EPMC2395211 | biostudies-literature
| S-EPMC7955066 | biostudies-literature
| S-EPMC9744130 | biostudies-literature